CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
ZD6474drug
Likely dose
ZD6474 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00410189
NCT00410189Phase 2Completed
CompareCT.gov

A Phase II, Open Label Study of ZD6474 in Previously Treated Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)

M.D. Anderson Cancer Center·interventional·Posted Dec 12, 2006·Updated Mar 23, 2015

In Brief

A Phase 2 clinical trial evaluating ZD6474 for Lung Cancer. Completed, enrolled 54 participants across 1 site.

Detailed Summary

Primary Objective: * To determine the 8 week progression-free survival rate (i.e. disease control rate) in patients with advanced NSCLC who have failed at least one prior chemotherapy regimen. Secondary Objectives: * Determine the overall response rate * Determine the overall survival * Determine the time to disease progression * Assess the safety/toxicity of the study treatment * Assess biomarker modulation in the tumor tissue and serum samples from the treatment * Assess plasma and intra-tumor concentrations of study treatment

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsUnited States Department of Defense, AstraZeneca

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 12, 2006
Enrollment StartNov 1, 2006
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 19.6 years ago

Interventions

ZD6474drug

300 mg by mouth daily for 28 Days.